美国 · 股市与财经 · Yahoo Finance
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials…
在 Yahoo Finance 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finance.yahoo.com)
.jpg)
